Actions of heparin that may affect the malignant process

Cancer

Volumn 85, Issue 2, 1999, Pages 257-272

  Engelberg, Hyman ^a  

^a California Arteriosclerosis Res F   (United States)

Author keywords

Cancer; Heparin; Metastasis

Indexed keywords

CASEIN KINASE II; CHEMOKINE; COMPLEMENT; DNA TOPOISOMERASE; FIBRIN; HEPARANASE; HEPARIN; HISTAMINE; MATRIX METALLOPROTEINASE; PLATELET DERIVED GROWTH FACTOR; PROTEOHEPARAN SULFATE; REACTIVE OXYGEN METABOLITE; RNA DIRECTED DNA POLYMERASE; SCATTER FACTOR; SERINE PROTEINASE; THROMBOCYTE ACTIVATING FACTOR; THROMBOPLASTIN; THROMBOSPONDIN; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BLOOD CLOTTING; CANCER INHIBITION; CELL ADHESION; ENZYME INHIBITION; FIBRIN FORMATION; METASTASIS; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; VIRUS CARCINOGENESIS; VIRUS INHIBITION;

ANTICOAGULANTS; CARCINOGENICITY TESTS; ENZYME INHIBITORS; HEPARIN; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0032941869     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990115)85:2<257::AID-CNCR1>3.0.CO;2-2     Document Type: Review

References (243)

1. Engelberg H. Actions of heparin in the atherosclerotic process. Pharmacol Rev 1996;48:327-52.
2. Regelson W. Aninonic dyes, heparin, and heparinoids: the rediscovery of polyanionic tumor inhibitors. J Natl Cancer Inst 1989;81:1929-30.
3. Engelberg H. Evidence thai endogenous heparin activity deficiency may be an important factor in atherogenesis. Semin Thromb Hemost 1997;23:159-66.
4. Gorelick E, Berr WE, Huberman RB. Role of NK cells in the antimetastatic effect of anticoagulant drugs. Int J Cancer 1984;33:87-94.
5. Gunji Y, Gorelick E. Role of fibrin coagulation in protection of murine tumor cells from destruction by cytotoxic cells. Cancer Res 1988;48:5216-21.
6. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983;62:14-31.
7. Nierodzik ML, Plotkin A, Kojumo F, Karpatkin S. Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. J Clin Invest 1991;87:229-36.
8. Markus G. The role of hemostasis and fibrinolysis in the metastatic spread of cancer. Thromb Hemost 1984;10:61-72.
9. Zhang Y, Deng Y, Luther T, Miller M, Ziegler R, Waldherr R, et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994;94:1320-7.
10. Karpatkin S, Nierodzik ML, Klepfish A. Role of platelets and thrombin in cancer. Vessels 1996;2:17-30.
11. Dvorak HF, Senger DR, Dvorak AM, Harvey VS, McDonagh J. Regulation of extravascular coagulation by microvascular permeability. Science 1985;227:1059-61.
12. Yanase T, Tamura M, Fujita K, Kodama S, Tanaka K. Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res 1993;53:2566-70.
13. Folkman J, Langer R, Linhardt R, Haudenschild C, Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 1983;221:719-25.
14. Weinstat-Saslow D, Steeg PS. Angiogenesis and colonization in the tumor metastatic process: basic and applied advances. FASEB J 1994;8:401-7.
15. Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JI, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989;84:1470-8.
16. Claffey KP, Brown LF, del Aquila LF, Tognazzi K, Yen KT, Manseau EJ et al. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis and experimental metastasis. Cancer Res 1996;56:172-81.
17. Doerr R, Zvibel I, Chiuten D, D'Olsinpro J, Reid LM. Clonal growth of tumors on tissue-specific biomatrices and correlation with organ site specificity of metastases. Cancer Res 1989;49:384-92.
18. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989;246:1309-12.
19. Koch ARE, Polverini PJ, Kunkel SL, Harlow A, DiPietro LA, Elner VM, et al. Interleukin-8 is a macrophage-derived mediator of angiogenesis. Science 1992;258:1798-1801.
20. Arenberg DA, Kunkel SL, Polverini PJ, Glass M, Burdick MD, Streiter RM. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest 1996;97:2792-2802.
21. Miller MD, Krangel MS. Biology and biochemistry of the chemokines: a family of chemotactic and inflammatory cytokines. Crit Rev Immunol 1992;12:17-46.
22. Camussi G, Montrucchio G, Lupia E, Soldi R, Conoglio PM, Bussolino F. Angiogenesis induced in vivo by hepatocyte growth factor is moderated by platelet activating factor synthesis from macrophages. J Immunol 1997;158:1302-9.
23. Lamazus K, Joseph A, Jin L, Yao Y, Chowdhury S, Fuchs A, et al. Scatter factor binds to thrombospodin and other extra-cellular matrix components. Am J Pathol 1996;149:805-19.
24. Rosen EM, Nigam SK, Goldberg ID. Scatter factor and the c-met receptor: a paradigm for mesenchymal/epithelial interaction. J Cell Biol 1994;127:1783-7.
25. Rong S, Bodescot M, Blair D, Dunn J, Nakamura T, Mizuno T, et al. Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol Cell Biol 1992;12: 5152-8.
26. Rosen EM, Knesel J, Goldberg ID. Scatter factor and its relationship in hepatocyte growth factor and metastasis. Cell Growth Diff 1991;2:603-7.
27. Verheul HMW, Horkmann K, Bakker SL, Erkman CA, Folman CC, Broxterman HJ, et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997;3: 2187-90.
28. Mohle R, Green D, Moore MAS, Nachman RJ, Rafii S. Constitutive production and thrombin-induced release of VEGF by human megakaryocytes and platelets. Proc Natl Acad Sci 1997;94:657-62.
29. Keyt BA, Nguyen HV, Berleau LT, Duarte CM, Park I, Chen H, et al. Identification of VEGF determinants for binding KDR and Flt-1 receptors, generation of receptor-selective VEGF variants. J Biol Chem 1996;271:5638-46.
30. Jackson RL, Busch SJ, Cardin AD. Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. Physiol Rev 1991;71:481-539.
31. Osband ME, Hamilton D, Shen Y-J, Cohen E, Schlesinger M, Brown A, et al. Successful tumour immunotherapy with cimetidine in mice, Lancet 1981;1:636-8.
32. Gifford RRM, Ferguson RM, Voss BV. Cimetidine reduction of tumor formation in mice. Lancet 1981;1:636-8.
33. Bartholegus J, Bouclier M. Involvement of histamine in growth of mouse and rat tumors. Antitumor properties of an enzyme-activated irreversible inhibitor of histidine decarboxylase. Cancer Res 1984;44:639-45.
34. Aruffo A, Dietsch MT, Wan H, Hellstrom KE, Hellstrom I. Granule membrane protein 140 (GMP 140) binds to carcinomas and carcinoma-derived cell lines. Proc Natl Acad Sci 1992;89:2292-6.
35. Nair MPN, Schwartz SA. Effect of histamine and histamine antagonists on natural and antibody-dependent cellular cytotoxicity of human lymphocytes in vitro. Cell Immunol 1983;81:45-60.
36. Tilly BC, Tertoolen LGJ, Remorie R, Ladoux A, Verlaan I, de Laaf SW, et al. Histamine is a growth factor and chemoattractant for human carcinoma and melanoma cells. J Cell Biol 1990;110:1211-5.
37. Lucio J, Brot JD, Guo CB, Abraham WM, Lichtenstein LM, Kagey-Sobotka A, et al. Immunological mast cell-mediated responses and histamine release are attenuated by heparin. J Appl Physiol 1992;73:1093-1101.
38. Inase N, Schrek RE, Lazarus SC. Heparin inhibits histamine release from canine mast cells. Am J Physiol 1993;264:L387-90.
39. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76: 301-14.
40. Kojima N, Handa K, Newman W, Hakamori S-I. Inhibition of selectin-dependent tumor cell adhesion to endothelial cells and platelets by blocking O-glycosylation of these cells. Biochem Biophys Res Commun 1992;182:1288-95.
41. x as a new tumor-associated antigen. Cancer Res 1984;44:5279-85.
42. Fox SB, Turner GDH, Gatter KC, Harris AL. The increased expression of adhesion molecules ICAM-3, E-and P-selectins on breast cancer endothelium. J Pathol 1995;177:369-76.
43. Biancone L, Araki M, Araki K, Vasalli P, Stamenkovic I. Redirection of tumor metastasis by expression of E-selectin in vivo. J Exp Med 1996;183:581-7.
44. Goetz DG, Brandley BK, Hammer DA. An E-selectin-IgG chimera supports sialylated moiety dependent adhesion of colon cancer cells under fluid flow. Ann Biomed Eng 1996; 24:87-98.
45. Rosen SD, Bertozzi CR. The selectins and their ligands. Curr Opin Cell Biol 1994;6:663-73.
46. Sawada R, Tsuboi S, Fukuda M. Differential E-selectin-dependent adhesion efficiency in sublines of a human colon cancer exhibiting distinct metastatic potentials. J Biol Chem 1994;269:1425-31.
47. Beuth J, Ko HL, Pulverer G, Uhlenbrock G, Pichlmaier H. Importance of lectins for the prevention of bacterial infections and cancer metastasis. Glyconjugates 1995;12:1-6.
48. x, and sulfated glycans modulate this binding. Biochem Biophys Res Commun 1991;181:123-30.
49. Nelson RM, Ceccioni D, Roberts WG, Aruffo A, Lindhardt RJ, Bevilacqua MP. Heparin oligosaccharides bind L-and P-selectins and inhibit acute inflammation. Blood 1993;82: 3253-8.
50. Norgard-Sunnicht KE, Varki NM, Varki A. Calcium dependent heparin-like ligands for L-selectin in non-lymphoid endothelial cells. Science 1993;261:480-3.
51. Sears P, Wong C-H. Intervention of carbohydrate recognition by proteins and nucleic acids. Proc Natl Acad Sci 1996; 93:12086-93.
52. Satoh H, Ishikawa H, Kamma H, Yamashita YT, Takahashi H, Otsuka M, et al. Serum Sialyl Lewis X antigen levels in non small cell lung cancer: correlation with distant metastasis and survival. Clin Cancer Res 1997;3:495-9.
53. Bartolazzi A, Peach R, Aruffo A, Stamenkovic I. Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J Exp Med 1994;180:53-66.
54. Sy MS, Guo Y-J, Stamenkovic I. Inhibition of tumor growth in vivo with a soluble CD44-immunoglobulin fusion protein. J Exp Med 1992;176:623-7.
55. Laurent TC, Fraser JRE. Hyaluronan. FASEB J 1992;6:2397-2404.
56. Howard OMZ, Ben-Baruch A, Oppenheim JJ. Chemokines: progress toward identifying molecular targets for therapeutic agents. Trends Biotechnol 1996;14:46-51.
57. Kilgore KS, Flory CM, Miller BF, Evans VM, Warren JS. The membrane attack complex of complement induces IL-8 and MCP-1 secretion by human umbilical vein endothelial cells. Am J Pathol 1996;149:953-61.
58. Tanaka Y, Kimata K, Wake A, Mine S, Morimoto I, Yamakawa N. Heparan sulfate proteoglycans on leukemic cells is primarily involved in integrin triggering and its mediated adhesion to endothelial cells. J Exp Med 1996;184:1987-97.
59. Hayashi S, Kurchowska A, Cohen AB, Stevens MD, Fujisawa N. A synthetic peptide inhibitor for α-chemokines inhibits the growth of melanoma cell lines. J Clin Invest 1997;99: 2581-7.
60. Conti P, Pang X, Boucher W. Impact of RANTES and MCP-1 chemokines on in vivo basophilic cell recruitment in rat skin injection model and their role in modifying the protein and mRNA levels for histidine decarboxylase. Blood 1997;89: 4120-7.
61. Singh RK, Gutman M, Reich R, Bar-Eli M. Ultraviolet B irradiation promotes tumorigenic and metastatic properties in primary cutaneous melanoma via induction of IL-8. Cancer Res 1995;55:3669-74.
62. Orr FW, Delikatny EJ, Mokashi S, Krepart GV, Stiver HG. Detection of a complement-derived chemotactic factor for tumor cells in human inflammatory and neoplastic effusions. Am J Pathol 1983;110:41-7.
63. Orr FW, Adamson IYR, Young L. Pulmonary inflammation generates chemotactic activity for tumor cells and promotes lung metastasis. Am Rev Resp Dis 1985;131:607-11.
64. Niculescu F, Rus HG, Retegan M, Vlaicu R. Persistent complement activation on tumor cells in breast cancer. Am J Pathol 1992;140:1039-43.
65. Rubin JS, Chan AM-L, Bottaro DP, Burgess WH, Taylor WG, Cech AC. A broad spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor. Proc Natl Acad Sci 1991;88:415-9.
66. Rong S, Bodescot M, Blair D, Dunn J, Nakamura T, Mizuno K, et al. Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol Cell Biol 1992;12: 5152-8.
67. Naides YM, Rosen EM, Zitnick R, Goldberg I, Park M, Naujokas M, et al. Role of scatter factor in the pathogenesis of AIDS-related Kaposi sarcoma. Proc Natl Acad Sci 1994;91: 5281-5.
68. Jeffers M, Rong S, Vande-Woude GF. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/ scatter factor-met signaling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol 1996;16:1115-25.
69. Mars WM, Zamegar GK, Michalopoulos GK. Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Am J Pathol 1993;143:349-58.
70. Koochekpour S, Jeffers M, Rulong S, Taylor G, Klineberg E, Hudson EA, et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 1997;57: 5391-8.
71. Jin L, Fuchs A, Schnitt SJ, Yao Y, Joseph A, Lamagus K, et al. Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer 1997;79:749-60.
72. Kawakami-Kimura N, Narita T, Ohmori K, Yoneda T, Matsumoto K, Nakamina T, et al. Inducement of hepatocyte growth factor in increased integrin expression on HepG2 cells triggered by adhesion to endothelial cells. Br J Cancer 1997;75:47-53.
73. Mizumo K, Inoue H, Hagiya M, Shimizu S, Noar T, Shimohigashi Y, et al. Hairpin loop and second kringle domain are essential sites for heparin binding and biological activity of hepatocyte growth factor. J Biol Chem 1994;269:1131-6.
74. Clanton DJ, Jariwalla RJ, Kress C, Rosenthal LJ. Neoplastic transformation by a cloned human cytomegalovirus DNA fragment uniquely homologous to one of the transforming regions of herpes simplex virus type 2. Proc Natl Acad Sci 1983;80:3826-30.
75. Muganda PM, Fischer A, Bernal RA. Identification of a casein kinase activity found elevated in human cytomegalovirus transformed cells. Biochem Biophys Res Comm 1995;207: 740-6.
76. Sinatt J, Cinatti J, Vogel JU, Kotchatkov R, Driever PH, Kabickova H, et al. Persistent human cytomegalovirus infection induces drug resistance and alteration of programmed cell death in human neuroblastoma cells. Cancer Res 1998;58: 367-72.
77. Laurence J. Molecular interactions among herpesviruses and human immunodeficiency viruses. J Infect Dis 1990;162: 338-46.
78. Smith PR, Gao Y, Karran L, Jones MD, Snudden D, Griffin BE. Complex nature of the major viral polyadenylated transcripts in Epstein-Barr virus-associated tumors. J Virol 1993; 67:3217-25.
79. Vaheri A. Heparin and related polyanionic substances as virus inhibitors. Acta Pathol Microbiol Scand 1964;171:Supp 7-13.
80. Choi VC, Swack NS, Hsiung GD. Effect of heparin on cytomegalovirus replication. Proc Soc Exp Biol Med 1978;157: 369-75.
81. Ebbeson P. DEAE-dextran and polybrene cation enhancement and dextran sulfate inhibition of immune cytolysis. J Immunol 1972;109:1296-1301.
82. Hosoya M, Balzirini J, Shigeta S, DeClerq E. Differential inhibitory effects of sulfated polysaccharides and polymers on the replication of various myxoviruses and retroviruses depending on the composition of the target amino acid sequences of the viral envelope glycoproteins. Antimicrob Agents Chemother 1991;35:2515-20.
83. Reilly CF. Rat vascular smooth muscle cells immortalized with SV40 large T antigen possess defined smc characteristics, including growth inhibition by heparin. J Cell Physiol 1990;142:342-51.
84. Borek C, Ong A, Mason H, Donahue L, Bigalow JE. Selenium and vitamin E inhibit radiogenic and chemically induced transformation in vitro via different mechanisms. Proc Natl Acad Sci 1986;83:1490-4.
85. Weitberg AB, Weitzman SA, Destrempes M, Lott SA, Stossel TP. Stimulated human phagocytes produce cytogenetic changes in cultured mammalian cells. New Engl J Med 1983; 308:26-30.
86. Crawford D, Abinden I, Amstad P, Cerutti P. Oxidant stress induces the proto-oncogenes c-fos and c-myc in mouse epidermal cells. Oncogene 1988;3:27-32.
87. Lesko SA, Lorentzen RJ, Tso POP. Role of superoxide in deoxyribonucleic acid strand scission. Biochemistry 1980;19: 3023-8.
88. Knauper V, Wilhelm SM, Seperack PK, DeClerck YA, Langley KE, Osthnes A, et al. Direct activation of human neutrophil procollagenase by recombinant stromelysin. Biochem J 1993;295:581-6.
89. Wung BS, Cheng JJ, Hsieh HJ, Shyy YJ, Wang DL. Cyclic strain-induced MCP-1 gene expression in endothelial cells involves reactive oxygen species activation of AP-1. Circ Res 1997;81:1-7.
90. Marsh JP, Mossman BT. Role of asbestos and reactive oxygen species in activation and expression of ornithine decarboxylase in hamster tracheal epithelial cells. Cancer Res 1991;51:167-73.
91. Lang CA, Naryshkin S, Schneider DL, Mills BJ, Lindeman RD. Low blood glutathione levels in healthy aging adults. J Lab Clin Med 1992;120:720-5.
92. Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J 1996;313:17-29.
93. Rodriguez H, Holmquist GP, D'Agostino R, Keller J, Akman SA. Metal ion-dependent hydrogen peroxide-induced DNA damage is more sequence specific than metal specific. Cancer Res 1997;57:2394-403.
94. Hiebert L, Ping T. Protective effects of dextran sulfate and heparin on adult rat cardiomyocytes damaged by free radicals. J Mol Cell Cardiol 1997;29:229-35.
95. Jaques LB. Heparin-anionic polyelectrolyte drugs. Pharmacol Rev 1980;31:99-166.
96. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993;73:161-95.
97. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993;9:541-73.
98. Chen WT. Membrane proteases: role in tissue remodeling and tumor invasion. Curr Opin Cell Biol 1992;4:802-9.
99. Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metalloprotease family members in breast cancer represents a tumor-induced host response. Am J Pathol 1996;149:273-82.
100. DeClerck YA, Perez N, Shimada H, Boone TC, Langley KE, Taylor SM. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 1992;52:701-8.
101. Alvarez DA, Carmichael DF, DeClerck YA. Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinase. J Natl Cancer Inst 1990;82:589-95.
102. Janoff A. Elastase in tissue injury. Annu Rev Med 1985;36: 207-16.
103. Okada Y, Watanabe S, Nakaneshi T, Kishi J-I. Inactivation of tissue inhibitor of metalloproteinases by a neutrophil elastase and other serine proteases. FEBS Lett 1988;229:57-60.
104. Pei D, Weiss SJ. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 1995;375:244-7.
105. Pegg AE. Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy. Cancer Res 1988;48:759-74.
106. Smith MK, Goral MA, Wright JH, Matrisian LM, Morris RJ, Klein-Szanto AJP, et al. Ornithine decarboxylase overexpression leads to increased epithelial tumor invasiveness. Cancer Res 1997;57:2104-8.
107. Pegg AE. Recent advances in the biochemistry of polyamines in eukaryotes. Biochem J 1986;234:249-62.
108. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990;8:121-5.
109. Peppin GJ, Weiss SJ. Activation of the endogenous metalloproteinase, gelatinase, by triggered human neutrophils. J Biol Chem 1986;83:4322-6.
110. Parsons SL, Watson SA, Brown PD, Steel RCG. Matrix metalloproteinases. Br J Surg 1997;84:160-6.
111. Nerlov C, Rorth P, Blasi F, Johnsen M. Essential AP-1 and PEA-3 binding elements in the human urokinase enhancer display cell type-specific activity. Oncogene 1991;6:1583-92.
112. Mauviel A. Cytokine regulation of matrix metalloproteinase gene expression. J Cell Biochem 1993;53:288-95.
113. Tina-Au YP, Kenagy RD, Clowes AW. Heparin selectively inhibits the transcription of tissue-type plasminogen activator in primate arterial smooth muscle cells during mitogenesis. J Biol Chem 1992;267:3438-44.
114. Busch SJ, Martin GA, Barnhart RL, Mano M, Cardin AD, Jackson RL. Trans-repressor activity of nuclear glycosaminoglycans on Fos and Jun/AP-1. J Cell Biol 1992;116:31-42.
115. Wrenshall LE, Cerra FB, Singh RK, Platt JL. Heparan sulfate initiates signals in murine macrophages leading to divergent biologic outcomes. J Immunol 1995;154:871-80.
116. Tina-Au YP, Dobrowolska G, Morris DR, Clowes AW. Heparin decreases activator protein-1 binding to DNA in part by posttranslational modification of Jun B. Circ Res 1994;74:15-22.
117. Jaques LB. Heparins-anionic polyelectrolyte drugs. Pharmacol Rev 1980;31:99-166.
118. Furcht LT, Skubitz APN, Fields GB. Tumor cell invasion, matrix metalloproteases and the dogma. Lab Invest 1994;70: 781-3.
119. Saksela O, Rifkin DB. Cell-associated plasminogen activation: regulation and physiological functions. Annu Rev Cell Biol 1988;4:93-126.
120. Reich R, Thompson EW, Iwamoto Y, Martin GR, Deason JR, Fuller GC, et al. Effects of inhibitors of plasminogen activators, serine proteases and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res 1988; 48:3307-12.
121. Owen CA, Campbell MA, Sannes PL, Bonkeder SS, Campbell EJ. Cell surface-bound elastase and cathepsin G on human neutrophils: a novel non-oxidative mechanism by which neutrophils focus and preserve catalytic activity of serine proteinases. J Cell Biol 1995;131:775-89.
122. Dang QD, Gunito ER, DiCera E. Rational engineering of activity and specificity in a serine protease. Nat Biotechnol 1997;15:146-9.
123. Mullins DE, Rohrlich ST. The role of proteinases in cellular invasiveness. Biochim Biophys Acta 1983;695:177-214.
124. Hanks SK. Homology probing: identification of cDNA clones encoding members of the protein serine kinase family. Proc Natl Acad Sci 1987;84:388-92.
125. Liotta LA, Rao CN, Wewer UM. Biochemical interactions of tumor cells with the basement membrane. Annu Rev Biochem 1986;55:1037-57.
126. Farrell DH, Cunningham DD. Human fibroblasts accelerate the inhibition of thrombin by protease nexin. Proc Natl Acad Sci 1986;83:6858-62.
127. Low DA, Baker JB, Koon WL, Cunningham DD. Released protease nexin regulates cellular binding, internalization, and degradation of serine proteases. Proc Natl Acad Sci 1981;78:2340-4.
128. Gralnick HR. von Willebrand factor, integrins, and platelets: their role in cancer. J Lab Clin Med 1992;119:444-7.
129. Bitan M, Mohsen M, Levi E. Structural requirements for inhibition of melanoma lung colonization by heparanase inhibitory species of heparin. Isr J Med Sci 1995;31:106-18.
130. Parish CR, Coombe DR, Jacobsen KB, Bennett FA, Underwood PA. Evidence that sulphated polysaccharides inhibit tumor metastases by blocking tumor cell-derived heparanases. Int J Cancer 1987;40:511-8.
131. Vlodavsky I, Ishai-Michaels R, Mohren M, Bar-Shavit R, Catani R, Ekre H-P, et al. Modulation of neovascularization and metastasis by species of heparin. Adv Exp Biol Med 1992;313:317-27.
132. Lapierre F, Holme K, Lam L. Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, antitumor, and anti-metastatic properties. Glycobiology 1996;6:355-66.
133. Tuszynski GP, Smith M, Rothman VL, Capuzzi DM, Joseph RR, Katz J, et al. Thrombospodin levels in patients with malignancy. Thromb Haemost 1992;67:607-11.
134. Gawaz M, Ott I, Reininger AJ, Heinzmann V, Newmann F-J. Agglutination of isolated platelet membranes. Arterioscler Thromb Vasc Biol 1996;16:621-7.
135. Wong SY, Pardie AT, Han P. Thrombospodin and other possible related matrix proteins in malignant and benign breast tissue: an immunohistochemical study. Am J Pathol 1992;140:1473-82.
136. Taraboletti G, Roberts DD, Liotta LA. Thrombospodin-induced tumor cell migration: hapotaxis and chemotaxis are mediated by different molecular domains. J Cell Biol 1987; 105:2409-15.
137. Tuszynski GP, Rothman VL, Papale M, Hamilton BK, Eyal J. Identification and characterization of a tumor cell acceptor for CSVTCG, a thrombospodin adhesive domain. J Cell Biol 1993;120:513-21.
138. Castle V, Varani J, Fligiel S, Prochonik EV, Dixit V. Antisense-mediated reduction in thrombospodin reverses the malignant phenotype of a human squamous carcinoma. J Clin Invest 1991;87:1883-8.
139. Schon P, Vischer P, Volker W, Schmidt A, Faver V. Cell associated proteo-heparan sulfate mediates binding and uptake of thrombospodin in cultured porcine vascular endothelial cells. Eur J Cell Biol 1992;59:329-39.
140. Yagel S, Khokha R, Denhardt DT, Kerbel RS, Parker RS, Lala PK. Mechanisms of cellular invasiveness: a comparison of amnion invasion in vitro and metastatic behavior in vivo. J Natl Cancer Inst 1989;81:768-75.
141. Murphy-Ullrich JE, Mosher DF. Interactions of thrombospodin with endothelial cells. J Cell Biol 1987;105:1603-11.
142. Lyons-Giordano E, Brinker JM, Kefalides NA. Heparin coordinately suppresses endothelial cell fibronectin and thrombospodin expression. J Cell Biol 1990;111:abst 293.
143. Takagi J, Fugisawa T, Usui T, Koyama T, Saito Y. A single-chain 19-kDa fragment from bovine thrombospodin binds to type V collagen and heparin. J Biol Chem 1993;268: 15544-9.
144. Hogg PJ, Owensby DA, Chesterman CN. Thrombospodin-1 is a tight-binding competitive inhibitor of neutrophil cathepsin G. J Biol Chem 1993;268:21811-8.
145. Drake SL, Klein OJ, Mickelson DJ, Oegema TR, Furcht LT, McCarthy JB. Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycans initiate mouse melanoma cell adhesion to fibronectin-derived heparin-binding synthetic peptides. J Cell Biol 1992;117:1331-41.
146. Timar J, Ladanyl A, Lapia K, Moczar M. Differential expression of proteoglycans on the surface of human melanoma cells characterized by altered experimental metastatic potential. Am J Pathol 1992;141:467-74.
147. Tovari J, Paku S, Raso E, Pogany G, Kovalszky I, Ladanyi A, et al. Role of sinusoidal heparan sulfate proteoglycans in liver metastasis formation. Int J Cancer 1997;71:825-31.
148. Charonis AS, Skubitz APN, Koliakov GC, Reger LA, Dege J, Vogel AM, et al. A novel synthetic peptide from the B chain of laminin with heparin-binding and cell adhesion-promoting properties. J Cell Biol 1988;107:1253-60.
149. McCarthy JB, Chelberg MK, Mickelson DJ, Furcht LT. Localization and chemical synthesis of fibronectin peptides with melanoma adhesion and heparin-binding activities. Biochemistry 1988;27:1330-8.
150. Morrison RF, Seidel ER. Vascular endothelin cell proliferation: regulation of cellular polyamines. Cardiovasc Res 1995; 29:841-7.
151. Packham G, Cleveland JL. Ornithine decarboxylase is a mediator of c-myc-induced apoptosis. Mol Cell Biol 1994;14: 5741-7.
152. Auvinen M, Paasinen A, Andersson LC, Holtta E. Ornithine decarboxylase activity is critical for cell transformation. Nature 1992;360:355-8.
153. Smith MK, Goral MA, Wright JH, Matrisian LM, Morris RJ, Klein-Szanto AJP, et al. Ornithine decarboxylase overexpression leads to increased epithelial tumor invasiveness. Cancer Res 1997;57:2104-8.
154. O'Brien TG, Megosh LC, Gilliard G, Soler AP. Ornithine decarboxylase overexpression is a sufficient condition for tumor formation in mouse skin. Cancer Res 1997;57:2630-7.
155. Pegg AE. Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy. Cancer Res 1988;48:759-74.
156. Pegg AE. Recent advances in the biochemistry of polyamines in eukaryotes. Biochem J 1986;234:249-62.
157. Auvinen M, Laine A, Paasinwn-Sohns A, Kangas A, Kangas L, Saksela O, et al. Human ornithine decarboxylase-overproducing NIH3T3 cells induce rapidly growing, highly vascularized tumors in nude mice. Cancer Res 1997;57:3016-25.
158. Singh LP, Aroor AR, Wahba AJ. Inhibition of rabbit reticulocyte guanine nucleotide exchange factor activity by heparin and its reversal by polyamines. Biochem Biophys Res Commun 1995;212:1007-14.
159. Tabib A, Bachrach U. Activation of the proto-oncogenes c-myc and c-fos by c-rav: involvement of polyamines. Biochem Biophys Res Commun 1994;202:720-7.
160. 2-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem 1994;269:4355-79.
161. Engelberg H. Serum lipemia: an overlooked cause of tissue hypoxia. Cardiology 1981;70:273-9.
162. Sporn MB, Roberts AB. Transforming growth factor-β: recent progress and new challenges. J Cell Biol 1992;119:1017-21.
163. Kubata S, Fridman R, Yamada Y. Transforming growth factor-β suppresses the invasiveness of human fibrosarcoma cells in vitro. Biochem Biophys Res Commun 1991;176:129-36.
164. Bereta J, Bereta M, Coffman FD, Cohen S, Cohen MC. Inhibition of basal and TNF-enhanced binding of murine tumor cells to murine endothelium by transforming growth factor-β. J Immunol 1992;148:2932-40.
165. Butta A, Madennan K, Flanders KC, Sarki NPM, Smith I, McKinna A, et al. Induction of transforming growth factor-β in human breast cancer in vivo following tamoxifen treatment. Cancer Res 1992;52:4261-4.
166. Knaus PI, Lindemann D, Decoteau JF, Perlman R, Yankelov Hillerta M. A dominant inhibitory mutant of the type II transforming growth factor-β receptor in the malignant progression of a cutaneous T cell lymphoma. Mol Cell Biol 1996;16:3480-9.
167. Garrigua-Antar L, Munoz-Antonia T, Antonia SJ, Gesmonde J, Villuci VF, Reise M. Missence mutations of the transforming growth factor-β type II receptor in human head and neck squamous carcinoma cells. Cancer Res 1995;55:3982-7.
168. Raynal S, Nocentini S, Croisy A, Lawrence DA, Jullien P. Transforming growth factor-β enhances the lethal effect of DNA-damaging agents in a human lung cancer cell line. Int J Cancer 1997;72:356-61.
169. McCaffrey TA, Falcone DJ, Vicente D, Du B, Consigli S, Borth W. Protection of transforming growth factor-β1 activity by heparin and fucoidan. J Cell Physiol 1994;159:51-9.
170. Land H, Parada LF, Weinberg RA. Cellular oncogenes and multistep carcinogenesis. Science 1983;62:771-8.
171. Weinberg RA. Oncogenes, anti-oncogenes and the molecular basis of multistep carcinogenesis. Cancer Res 1989;49: 3713-21.
172. Kato GJ, Dang CV. Function of the c-myc oncoprotein. FASEB J 1992;6:3065-72.
173. Shioda T, Munn L, Fenner NH, Jain RK, Isselbacher KJ. Early events of metastasis in the microcirculation involve changes in gene expression of cancer cells. Am J Pathol 1997;150: 2099-112.
174. Smeal T, Binstroy B, Mercola DA, Birrer M, Karin M. Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73. Nature 1990; 354:494-6.
175. Li J-J, Westergaard C, Ghosh P, Colburn NH. Inhibition of both Nf-KB and AP-1 activation block the neoplastic transformation response. Cancer Res 1997;57:3569-76.
176. Johnson RJ, Spiegelman B, Hanahan D, Wisdom R. Cellular transformation and malignancy induced by ras requires c-jun. Mol Cell Biol 1996;16:4504-11.
177. Fanjul A, Dawson MI, Hobbs PD, Jong L, Cameron JF, Harlev E, et al. A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature 1994;372:107-11.
178. Wright TC Jr., Pukac LA, Castellot JJ, Karnovsky MJ, Levine RA, Kim-Park H-Y, et al. Heparin suppresses the induction of c-fos and c-myc mRNA in murine fibroblasts by selective inhibition of a PKC-dependent pathway. Proc Natl Acad Sci 1989;86:3199-203.
179. Pukac LA, Castellot JJ, Wright TC, Caleb BL, Karnovsky MJ. Heparin inhibits c-fos and c-myc expression in vascular smooth muscle cells. Cell Regul 1990;1:435-43.
180. Wight TN, Kinsella MG, Qwarnstrom EE. The role of proteoglycans in cell adhesion, migration, and proliferation. Curr Opin Cell Biol 1992;4:793-801.
181. Au YP, Dobrowolska G, Morris DR, Clowes AW. Heparin decreases activator protein-1 binding to DNA in part by posttranslational modification of Jun B. Circ Res 1994;75:15-22.
182. Busch SJ, Martin GA, Barnhart RL, Mano M, Cardin AD, Jackson RL. Trans-repressor activity of nuclear glycosaminoglycans on fos and jun/AP-1 oncoprotein-mediated transcription. J Cell Biol 1992;116:31-42.
183. Smith LM, Birrer MJ, Stampfer MR, Brown PH. Breast cancer cells have lower AP-1 transcription factor activity than normal mammary epithelial cells. Cancer Res 1997;57:3046-54.
184. Kaina B, Haas S, Kappes H. A general role for c-fos in cellular protection against DNA-damaging carcinogens and cytostatic drugs. Cancer Res 1997;57:2721-31.
185. Tuazon PT, Traugh JA. CK1 and 11-multipotential serine protein kinases: structure, function, and regulation. Adv Second Messenger Phosphoprotein Res 1991;23:124-64.
186. Hathaway GM, Lubben TH, Traugh JA. Inhibition of casein kinase II by heparin. J Biol Chem 1980;255:8038-41.
187. Muganda PM, Fischer A, Bernal RA. Identification of a casein kinase activity found elevated in human cytomegalovirus transformed cells. Biochem Biophys Res Commun 1995; 207:740-6.
188. Luscher B, Kuenzel EA, Krebs EG, Eisenman RN. Myc onco-proteins are phosphorylated by casein kinase II. EMBO J 1989;8:1111-9.
189. Seldin DC, Leder P. Casein kinase 11a transgene-induced murine lymphoma: relation to theileriosis in cattle. Science 1995;267:894-7.
190. Krek W, Maridor G, Nigg EA. Casein kinase II is a predominantly nuclear enzyme. J Cell Biol 1992;116:43-55.
191. Filhol O, Boudier J, Delphin C, Loue-Mackenbach P, Chambaz EM, Cochet C. Casein kinase II and the tumor suppressor protein p53 associate in a molecular
192. Filhol O, Cochet C, Chambaz EM. DNA binding activity of casein kinase II. Biochem Biophys Res Commun 1990;173: 862-71.
193. Beutler E, Gelbart T, Kuhl W. Interference of heparin with the polymerase chain reaction. Biotechniques 1990;9:166-70.
194. Satangi J, Jewel DP, Welsh K, Bunce M, Bell JI. Effect of heparin on polymerase chain reaction. Lancet 1994;343: 1509-10.
195. Ishii K, Katase A, Andoh T, Seno N. Inhibition of topoisomerase by heparin. Biochem Biophys Res Commun 1982;104: 541-7.
196. Chen AK, Liu LF. DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 1994;34:191-218.
197. Wang JC. DNA topoisomerases. Annu Rev Biochem 1996;65: 635-92.
198. Feng J, Funk WD, Wang SS. The RNA component of human telomerase. Science 1995;269:1236-41.
199. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PCL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5.
200. Greider CW, Blackburn EH. Telomeres, telomerase and cancer. Sci Am 1996;274:92-7.
201. Parkinson ER. Do telomerase antagonists represent a novel anti-cancer strategy? Br J Cancer 1996;73:1-4.
202. Kordizaki GJ, Jakes S, Ingebritsen TS, Benbow RN. Casein kinase II stimulates Xenopus laevis DNA topoisomerase 1 by physical association. Biochem J 1994;33:13484-91.
203. Bojanowski EC, Filhol D, Cochet C, Chambaz EM, Larsen AK. DNA topoisomerase II and casein kinase II associate in a molecular complex that is catalytically active. J Biol Chem 1993;268:22920-6.
204. Caron PR, Watt P, Wang JC. The c-terminal domain of Saccharomyces cervisiae DNA topo II. Mol Cell Biol 1994;14: 3197-3207.
205. Cardenas ME, Dang Q, Glover CVC, Gasser SM. Casein kinase II phosphorylates the eukaryotic-speciflc C-terminal domain of topoisomerase II in vivo. EMBO J 1992;11:1785-93.
206. Allende JE, Allende CC. Protein kinase CK2: an enzyme with multiple substrates and a puzzling regulation. FASEB J 1995; 9:313-23.
207. Joyce CM, Steitz TA. Function and structure relationships in DNA polymerases. Annu Rev Biochem 1994;63:777-822.
208. Lingner J, Hughes TR, Shevchenko A, Mann M, Lundblad V, Cech TR. Reverse transcriptase motifs in the catalytic sub-unit of telomerase. Science 1997;276:561-7.
209. Weinrick SL, Pruzan R, Ma L, Oullette M, Tesmer VM, Holt SE, et al. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet 1997;17:498-502.
210. Cochran BH, Zullo J, Verma IM, Stiles CD. Expression of the c-fos gene and of a fos-related gene is stimulated by platelet-derived growth factor. Science 1984;226:1080-2.
211. Cross M, Dexter CM. Growth factors in development, transformation, and tumorigenesis. Cell 1991;64:271-80.
212. Kovalenko M, Gazit A, Bohmer A, Rorsman C, Ronnstrand L, Heldin C-H. Selective platelet-derived growth factor receptor kinase blockers reverse sis transformation. Cancer Res 1994;54:6106-14.
213. Vassbotic FS, Andersson M, Westermark B, Heldin C-H, Ostman A. Reversal of autocrine transformation by a dominant negative platelet-derived growth factor mutant. Mol Cell Biol 1993;13:4066-76.
214. Antoniades HN, Galanopoulos T, Neville-Golden J, Ohara CJ. Malignant epithelial cells in primary human lung carcinomas coexpressed in vivo PDGF and PDGF receptor mRNA and their protein products. Proc Natl Acad Sci 1992;89: 3942-6.
215. Hermansson MK, Funa K, Hartman M, Claesson-Welsh L, Heldin C-L, Westermark B, et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of mRNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 1992;42:3213-9.
216. Heldin C-H. Structural and functional studies on platelet derived growth factor. EMBO J 1992;11:4251-9.
217. Fager G, Camejo G, Bondgers G. The PDGF A-chain contains an amino acid sequence that specifically binds to heparin causing inactivation of the growth factor. Scand J Clin Invest 1990;199:33-6.
218. Corliss J. Heparin analogues: a new family of anti-cancer drugs. J Natl Cancer Inst 1992;84:1346-7.
219. Zweibel I, Halay E, Reid LM. Heparin and hormonal regulation of mRNA synthesis and abundance of autocrine growth factors: relevance to clonal growth of tumors. Mol Cell Biol 1991;11:108-16.
220. Vanucchi S, Pasquali F, Chiarugi VP, Ruggiero M. Heparin inhibits A431 cell growth independently of serum and EGF mitogenic signaling. FEBS Lett 1991;281:141-4.
221. Martin DE, Reese M, Reese AC. Effect of fibronectin, macrophages and glycosaminoglycans on tumor cell growth. Cancer Invest 1984;2:339-45.
222. Bertolesi GE, Lauria de Cidre L, Eijian AM. Growth inhibition in vitro of murine mammary adenocarcinoma cells by heparin and chemically modified heparins. Tumour Biol 1994;15:275-83.
223. Vasey PA, Kaye SB. Combined inhibition of topoisomerase 1 and 11: is this a worthwhile/feasible strategy? Br J Cancer 1997;76:1395-7.
224. Qi J, Goralnick S, Kreutzer DL. Fibrin regulation of interleukin-8 gene expression in human vascular endothelial cells. Blood 1997;90:3595-602.
225. Amberger VR, Hensel T, Ogata N, Schwab ME. Spreading and migration of human glioma and rat C6 cells on central nervous system myelin in vitro is correlated with tumor malignancy and involves a metalloproteolytic activity. Cancer Res 1998;58:149-58.
226. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997;72:1-22.
227. Hanahan D. A flank attack on cancer. Nat Med 1998;4:13-4.
228. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279:377-80.
229. Kitadai Y, Haruma K, Sumii K, Yamamoto S, Ue T, Yokozaki H, et al. Expression of interleukin-8 correlates with vascularity in human gastric carcinomas. Am J Pathol 1998;152: 93-100.
230. 2 in pathologic vascular growth. J Clin Invest 1997;100:2072-8.
231. Ashley DM, Kong FM, Bigner DB, Hale LP. Endogenous expression of transforming growth factor Beta-1 inhibits growth tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model. Cancer Res 1998; 58:302-9.
232. Coombe DR, Parish CR, Ramshaw TA, Snowden JM. Analysis of the inhibition of tumour metastasis by sulfated polysaccharides. Int J Cancer 1987;38:82-8.
233. Parsonnet J. Molecular mechanisms for inflammation-promoted pathogenesis of cancer: the sixteenth international symposium of the Sapporo cancer seminar. Cancer Res 1997; 57:3620-4.
234. Cao Y, O'Reilly MS, Marshall B, Flynn E, Ji RW, Folkman J. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest 1998;101:1055-63.
235. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CG, Freeman MR. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 1998; 58:1395-9.
236. Singh RK, Varney ML. Regulation of IL-8 expression in human malignant melanoma cells. Cancer Res 1998;58:1532-7.
237. Graham CH, Fitzpatrick TE, McCrae KR. Hypoxia stimulates urokinase receptor expression through a Heme protein-dependent pathway. Blood 1998;91:3200-7.
238. Mueller BM, Ruf W. Requirement for binding of catalytically active factor VIIa is tissue factor-dependent experimental metastasis. J Clin Invest 1998;101:1372-8.
239. Austin CA, Sng J-H, Patel S, Fisher LM. Novel HeLa topoisomerase II is the IIB isoform: complete coding sequence and homology with other type II topoisomerases. Biochim Biophys Acta 1993;1172:283-91.
240. Cheng C, Wang LK, Sekiguchi J, Shuman S. Mutational analysis of 39 residues of vaccine DNA topoisomerase identifies Lys 220, Arg 223, Asn 228 as important for covalent catalysis. J Biol Chem 1997;272:8263-9.
241. Petersen BO, Shuman S. Histidine 265 is important for covalent catalysis by vaccine topoisomerase and is conserved in all eukaryotic type 1 enzymes. J Biol Chem 1997;272: 3891-6.
242. Nakoyama J-i, Tahara H, Tahara E, Saito M, Ito K, Nakamura H, et al. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 1998; 18:65-8.
243. Harrington L, McPhail T, Mar V, Zhou W, Oultan R, Program A. A mammalian telomerase-associated protein. Science 1997;275:973-7.